248 patents currently held
11 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Dec 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
38
Ending by 2030
Dec 2026
Next term end
119
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2028 · High confidence
Also notable
Ends Jul 2036 · High confidence
Also notable
Ends no later than Nov 2027 · Medium confidence
Also notable
Ends Apr 2037 · High confidence
Also notable
Ends no later than Nov 2038 · Low confidence
Also notable
Ends Jan 2033 · Medium confidence
Also notable
Ends Dec 2035 · High confidence
Also notable
Ends Jun 2037 · High confidence
Antibodies to IL-6 and Use Thereof
US 7,935,340
The most cited patent in this portfolio, cited by 148 later US patents, top 5% of utility patents granted in 2011 in our data. Protection runs to 2028.
Agents, Uses and Methods for the Treatment of Synucleinopathy
US 11,542,323
Cited by 12 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.
Methods of Synthesizing Heteromultimeric Polypeptides in Yeast Using a Haploid Mating Strategy
US 7,927,863
Cited by 89 later US patents, top 10% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Humanized Anti-Pacap Antibodies and Uses Thereof
US 10,913,783
Cited by 29 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2037.
New Catecholamine Prodrugs for Use in the Treatment of Parkinson?s DISEA6S
US 11,707,476
Cited by 25 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2038. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Carbamate Compounds and of Making and Using Same
US 9,133,148
Cited by 55 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Humanized Anti-Acth Antibodies and Use Thereof
US 10,047,157
Cited by 29 later US patents, top 10% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
1H-Pyrazolo[4,3-b]pyridines as PDE1 Inhibitors
US 10,034,861
Cited by 24 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2037.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 18, 2026The maintenance fee for Pyrazole Compounds and Methods of Making and Using Same (US 10,323,038) comes due Dec 18, 2026. Unpaid by Jun 21, 2027, it lapses early.
- 11 fees due Jan 2 to 30, 2027 · next Jan 2
- 5 fees due Feb 13 to 28, 2027 · next Feb 13
- 2 fees due Mar 15, 2027
- 2 fees due Apr 1 to 10, 2027 · next Apr 1
- 7 fees due May 5 to 28, 2027 · next May 5
- 8 fees due Jun 10 to 30, 2027 · next Jun 10
- 6 fees due Jul 2 to 28, 2027 · next Jul 2
- 3 fees due Aug 4 to 18, 2027 · next Aug 4
- 3 fees due Sep 8 to 26, 2027 · next Sep 8
- 6 fees due Oct 12 to 28, 2027 · next Oct 12
- 4 fees due Nov 5 to 12, 2027 · next Nov 5
Recent changes
- Oct 13Assignment recorded on 1 record: Juhl, Karsten and 10 others to H. Lundbeck A/S Recorded Oct 13, 2026, executed Mar 20, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76355, frame 76.
- 2 of the patents on this record were granted since Aug 22, 2026
- 4 terms have ended since Aug 22, 2026
- Oct 11 US 11,466,027 Modulators of the Nmda Receptor · lapsed on the fee record
- Oct 9 US 10,093,635 Magl Inhibitors · lapsed on the fee record
- Oct 9 US 10,093,630 Pyrazole Compounds and Methods of Making and Using Same · lapsed on the fee record
- Sep 23 US 8,841,452 Process for Recovery of Nalmefene Hydrochloride · lapsed on the fee record
What they patent
The largest of its 119 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,544,685 | Novel 2,3-Dihydroindole Compounds In force · High confidence | In force | High confidence | |
| US 8,022,084 | Polymorphic Forms of a Gabaa Agonist In force · High confidence | In force | High confidence | |
| US 8,969,355 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment In force · High confidence | In force | High confidence | |
| US 9,095,588 | Process for Preparing 1-[2-(2,4-Dimethylphenylsulfanyl)-PHENY]PIPERAZINE or Pharmaceutically Acceptable Salt Thereof In force · Medium confidence | In force | Medium confidence | |
| US 9,101,626 | Process For Preparing 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine Or Pharmaceutically Acceptable Salt Thereof In force · High confidence | In force | High confidence | |
| US 9,125,908 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment In force · High confidence | In force | High confidence | |
| US 9,125,909 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment In force · Medium confidence | In force | Medium confidence | |
| US 9,125,910 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment In force · Medium confidence | In force | Medium confidence | |
| US 9,227,946 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment In force · High confidence | In force | High confidence | |
| US 9,744,166 | Therapeutic Uses of Compounds Having Combined SERT, 5-HT3 and 5-HT1A Activity In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 248: 11 patents in force now held by others · 316 patents ended · 34 applications pending · 268 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.